Kerri-Ann Millar
Director of Finance/CFO chez CUE BIOPHARMA, INC.
Fortune : 29 412 $ au 31/03/2024
Profil
Kerri-Ann Millar is currently the Chief Financial Officer at Cue Biopharma, Inc. since 2020.
Prior to this, she worked as a Controller at Flexion Therapeutics, Inc. from 2014 to 2017.
She completed her undergraduate degree at Boston University in 1992.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CUE BIOPHARMA, INC.
0,03% | 06/03/2024 | 15 562 ( 0,03% ) | 29 412 $ | 31/03/2024 |
Postes actifs de Kerri-Ann Millar
| Sociétés | Poste | Début |
|---|---|---|
| CUE BIOPHARMA, INC. | Director of Finance/CFO | 30/04/2018 |
Anciens postes connus de Kerri-Ann Millar
| Sociétés | Poste | Fin |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/09/2017 |
Formation de Kerri-Ann Millar
| Boston University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CUE BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
